Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy
References (33)
- et al.
High density lipoprotein as a protective factor against coronary artery disease: the Framingham study
Am J Med
(1977) Chemosuppression of breast cancer with tamoxifen: laboratory evidence and 3 future clinical investigations
Cancer Invest
(1988)Long-term adjuvant tamoxifen therapy for breast cancer
Breast Cancer Res Treat
(1990)Long-term adjuvant tamoxifen therapy for breast cancer: the prelude to prevention
Cancer Treat Rev
(1990)The strategic use of antiestrogens to control the development and growth of breast cancer
Cancer
(1992)- et al.
Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study
J Clin Oncol
(1990) Evaluation of paradigms for the management of breast cancer: a personal perspective
Cancer Res
(1992)- et al.
Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen
Atherosclerosis
(1984) - et al.
Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels
Breast Cancer Res Treat
(1988) - et al.
Serum lipoproteins and cardiovascular risk
Br J Cancer
(1988)
A pilot trials to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer
Br J Cancer
Effect of tamoxifen treatment on plasma lipids and lipoprotein lipid composition
J Clin Endocrinol Metab
Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer
Aust NZ J Surgery
Serum cholesterol reduction with tamoxifen
Breast Cancer Res Treat
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
Ann Intern Med
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node negative breast cancer
J Natl Cancer Inst
Cited by (46)
Selective estrogen receptor modulators (SERMs) affect cholesterol homeostasis through the master regulators SREBP and LXR
2021, Biomedicine and PharmacotherapyCitation Excerpt :Furthermore, we and others have shown that SERMs reduce cholesterol biosynthesis by inhibiting the activity of post-lanosterol enzymes [13,15,16]. These effects may account for the low levels of circulating cholesterol described in patients taking these drugs [15,17–19]. We have also found that SERMs block the egress of LDL-derived cholesterol from lysosomes, thus explaining the synergistic effect with LOV on LDLR expression in cell lines [13,14].
Tamoxifen affects glucose and lipid metabolism parameters, causes browning of subcutaneous adipose tissue and transient body composition changes in C57BL/6NTac mice
2015, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Furthermore, Tam treated animals showed increased serum levels of triglycerides and free fatty acids compared to control animals. Serum HDL, LDL and total cholesterol levels were comparable between the two groups, in spite of what was shown by previous investigations [13,14]. Higher levels of serum triglycerides and free fatty acids might be a direct consequence of the conversion from white to beige adipocytes, because as known from literature lipid droplets of brown and beige adipocytes are smaller and scattered throughout.
Blood chemistry profiles in menopausal women administered tamoxifen for breast cancer
1998, General PharmacologyWomen, dyslipoproteinemia, and estrogens
1998, Endocrinology and Metabolism Clinics of North AmericaConfounding Effects of Tamoxifen: Cautionary and Practical Considerations for the Use of Tamoxifen-Inducible Mouse Models in Atherosclerosis Research - Brief Report
2023, Arteriosclerosis, Thrombosis, and Vascular Biology